Paper41574656
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.
Mazariegos Herrera A and 3 others. J Antimicrob Chemother, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis. Papers, record 41574656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41574656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Phosphorylcholine | Major topic |
| Leishmaniasis, Visceral | Major topic |
| Antiprotozoal Agents | Major topic |
| Body Weight | Major topic |
| Humans | |
| Child | |
| Child, Preschool | |
| Male | |
| Female | |
| Administration, Oral | |
| Adolescent | |
| Infant | |
| Africa, Eastern |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| VR 2022-01251 | Swedish Research Council | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 42910531 | Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis-right-to-reply. | https://conductscience.org/library/papers/42910531 |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37380365 | Social determinants of visceral leishmaniasis elimination in Eastern Africa. | BMJ Glob Health | 2023 | https://conductscience.org/library/papers/37380365 | PubMed |
| 2 | 19594530 | Medication errors: prescribing faults and prescription errors. | Br J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19594530 | PubMed |
| 3 | 12043359 | 2000 CDC Growth Charts for the United States: methods and development. | Vital Health Stat 11 | 2002 | https://conductscience.org/library/papers/12043359 | PubMed |
| 4 | 22833634 | Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. | J Antimicrob Chemother | 2012 | https://conductscience.org/library/papers/22833634 | PubMed |
| 5 | 18519729 | Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18519729 | PubMed |
| 6 | 22693548 | Leishmaniasis worldwide and global estimates of its incidence. | PLoS One | 2012 | https://conductscience.org/library/papers/22693548 | PubMed |
| 7 | 38900786 | A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh. | PLoS Negl Trop Dis | 2024 | https://conductscience.org/library/papers/38900786 | PubMed |
| 8 | 23835940 | Modeling and simulation in clinical pharmacology and dose finding. | CPT Pharmacometrics Syst Pharmacol | 2013 | https://conductscience.org/library/papers/23835940 | PubMed |
| 9 | 22585212 | Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. | Antimicrob Agents Chemother | 2012 | https://conductscience.org/library/papers/22585212 | PubMed |
| 10 | 25642253 | Clinical Features and Laboratory Findings of Visceral Leishmaniasis in Children Referred To Children Medical Center Hospital, Tehran, Iran during 2004-2011. | Iran J Parasitol | 2014 | https://conductscience.org/library/papers/25642253 | PubMed |
| 11 | 30188978 | Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial. | Clin Infect Dis | 2019 | https://conductscience.org/library/papers/30188978 | PubMed |
| 12 | 30038039 | Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/30038039 | PubMed |
| 13 | 40113369 | Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas. | Lancet Child Adolesc Health | 2025 | https://conductscience.org/library/papers/40113369 | PubMed |
| 14 | 27627654 | Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. | PLoS Negl Trop Dis | 2016 | https://conductscience.org/library/papers/27627654 | PubMed |
| 15 | 32780098 | Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/32780098 | PubMed |
| 16 | 23425958 | Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. | Clin Infect Dis | 2013 | https://conductscience.org/library/papers/23425958 | PubMed |
| 17 | 36164254 | Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/36164254 | PubMed |
| 18 | 24170666 | Therapeutic options for visceral leishmaniasis. | Drugs | 2013 | https://conductscience.org/library/papers/24170666 | PubMed |
| 19 | 16817681 | WHO Child Growth Standards based on length/height, weight and age. | Acta Paediatr Suppl | 2006 | https://conductscience.org/library/papers/16817681 | PubMed |
| 20 | 34798033 | Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. | Lancet Glob Health | 2021 | https://conductscience.org/library/papers/34798033 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 40980123 | Optimization and prioritization of paediatric drugs for visceral leishmaniasis. | Front Pediatr | 2025 | https://conductscience.org/library/papers/40980123 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41574656
GET https://conductscience.org/api/papers/v1/41574656/references?page=2